More all-time highs are in the books for the major averages as a temporary fix to the government shutdown come through and earnings season starts off hot
But the real action is in happening in biotech stocks. A couple of big buyouts paved the way for some impressive biotech gains to kick off the new trading week.
First up, Celgene Corp. (NADSAQ:CELG) plunked down $9 billion to acquire Juno Therapeutics (NASDAQ:JUNO) and get ahold of its promising line of CAR-T cancer treatments. The announcement juiced JUNO shares by more than 25% on the day, bringing its five day gains to an eye-popping....More>>>